Skip to main content
Fig. 7 | Journal of Nanobiotechnology

Fig. 7

From: Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

Fig. 7

Profiles of tumor growth measured in B16OVA tumor bearing mice intravenously administered with three cycles (cycle/every 72 h) of different treatments: saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 or Targeted Dox liposome or immunoliposomes (LPF). Dox was intravenously administered at 3 mg/kg and tumor growth was measured twice a week. Lines represent the average and standard deviation of 6 mice per group of treatment and arrows the three administrations

Back to article page